The global human cytomegalovirus 65 kDa phosphoprotein market is anticipated to grow at a considerable CAGR during the forecast period. Human cytomegalovirus is a virus that causes lifelong infections in humans and is asymptomatic in healthy hosts. However, it can cause fatal diseases in individuals having a low immune system. The rise in HCMV is one of the factors accelerating the growth of the market. For instance, according to the British Society for Immunology, the HCMV is anticipated to have a prevalence of 55-100% within the human population, depending on different socioeconomic factors. Moreover, HCMV is the leading infectious cause of congenital abnormalities in the western world, affecting 1-1.25% of all live births. Thus, the rising prevalence of HCMV is anticipated to drive the growth of the global human cytomegalovirus 65 kDa phosphoprotein market during the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/human-cytomegalovirus-65-kda-phosphoprotein-market
Impact of COVID-19 Pandemic on Global Human Cytomegalovirus 65 kDa Phosphoprotein market
The COVID-19 Pandemic had resulted in a significant impact on the human cytomegalovirus 65 kDa phosphoprotein market. The restrictions and lockdowns have disrupted the supply chain owing to delayed business deals, especially in the area of pharmaceutical corporations. Moreover, the non–invasive surgeries were postponed to reallocate the resources to treat COVID-19 patients. Thus, factors such as lockdowns, restrictions, and social distancing have resulted in a negative impact on the global human cytomegalovirus 65 kDa phosphoprotein market.
Human Cytomegalovirus 65 kDa Phosphoprotein Market- Segmentation
By Type
- HB-101
- CyMVectin
- Asp-0113
- PepVax
By Application
- Brain Tumor
- Hematological Tumor
- Kidney Transplant Rejection
- Liver Transplant Rejection
A full report of Human Cytomegalovirus 65 kDa Phosphoprotein Market is available at: https://www.omrglobal.com/industry-reports/human-cytomegalovirus-65-kda-phosphoprotein-market
Human Cytomegalovirus 65 kDa Phosphoprotein Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AlloVir
- AlphaVax
- Helocyte, Inc.
- Microbiotix, Inc.
- Moderna, Inc.
- Noble Pharmacare Ltd.
- SL VaxiGen Inc.
- SpyBiotech
- Synklino A/S
- Takeda Pharmacuetical Co.,Ltd.
